Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis

Bibliography

• Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86:5-17
   PubMed Web of Science ®Google Scholar
• Rose P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother 2007;8:1903-21
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR. The red eye. Infectious conjunctivitis, keratitis, endophthalmitis, and periocular cellulitis. Infect Syndr Head Neck 1988;2:99-116
   Google Scholar
• Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician 1998;57:735-46
   PubMed Web of Science ®Google Scholar
• Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2006;2:CD001211
   Google Scholar
• Diamant JI, Hwang DG. Therapy for bacterial conjunctivitis. Ophthalmol Clin North Am 1999;12:15-20
   Google Scholar
• Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of state departments of health. J Pediatr Ophthalmol Strabismus 2007;44:101-5
   PubMed Web of Science ®Google Scholar
• Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2:378-424
   PubMed Web of Science ®Google Scholar
• Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004;49(Suppl 2):S73-8
   PubMed Web of Science ®Google Scholar
• Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 2004;15:316-20
   PubMedGoogle Scholar
• Scoper SV. Review of third- and fourth-generation fluoroquinolones in ophthalmology: in vitro and in vivo efficacy. Adv Ther 2008;25:979-94
   PubMed Web of Science ®Google Scholar
• Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-8
   PubMed Web of Science ®Google Scholar
• Asbell PA, Sahm DF, Shaw M, et al. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg 2008;34:814-18
   PubMed Web of Science ®Google Scholar
• Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:322-45
   PubMedGoogle Scholar
• Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003;3:359-71
   PubMed Web of Science ®Google Scholar
• Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49(Suppl 2):S79-83
   PubMed Web of Science ®Google Scholar
• Levinson BA, Rutzen AR. New antimicrobials in ophthalmology. Ophthalmol Clin North Am 2005;18:493-509
   PubMedGoogle Scholar
• Cavuoto K, Zutshi D, Karp CL, et al. Update on bacterial conjunctivitis in South Florida. Ophthalmology 2008;115:51-6
   PubMed Web of Science ®Google Scholar
• Miller D, Flynn PM, Scott IU, et al. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol 2006;124:479-83
   PubMed Web of Science ®Google Scholar
• Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Infect Control 2006;34:S38-45
   PubMed Web of Science ®Google Scholar
• Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J 2005;24:823-8
   PubMed Web of Science ®Google Scholar
• Brown L. Resistance to ocular antibiotics: an overview. Clin Exp Optom 2007;90:258-62
   PubMed Web of Science ®Google Scholar
• Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther 2007;23:243-56
   PubMed Web of Science ®Google Scholar
• Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2):S120-6
   PubMed Web of Science ®Google Scholar
• Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2009;63:443-50
   PubMed Web of Science ®Google Scholar
• Yague G, Morris JE, Pan X-S, et al. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother 2002;46:413-19
   PubMed Web of Science ®Google Scholar
• Zhang J-Z, Cavet ME, Ward KW. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Curr Eye Res 2008;33:923-32
   PubMed Web of Science ®Google Scholar
• Zhang J-Z, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother 2008;61:111-16
   PubMed Web of Science ®Google Scholar
• Protzko E, Bowman L, Abelson M, et al. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2007;48:3425-9
   PubMed Web of Science ®Google Scholar
• McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999;12:147-79
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Borsos S, Hesje CK. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J Chemother 2007;19:146-51
   PubMed Web of Science ®Google Scholar
• Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009;53:3552-60
   PubMed Web of Science ®Google Scholar
• Haas W, Zurenko GE, Lee J, et al. Activity of besifloxacin and comparators against ciprofloxacin resistant Staphylococcus aureus and Staphylococcus epidermidis ocular isolates from 2005–2008. Poster presented at the 3rd Congress of the Federation of European Microbiologists (FEMS), 28 June – 2 July 2009 Goteborg, Sweden
   Google Scholar
• Haas W, Brunner LS, Pillar C, Morris TW. Bactericidal activity of besifloxacin and other ophthalmic antibacterials against recent ocular isolates. Invest Ophthalmol Vis Sci 2009;50:e-abstract 2675
   Google Scholar
• Proksch J, Driot J-Y, Ward KW. Nonclinical ocular and systemic pharmacokinetics of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. Invest Ophthalmol Vis Sci 2007;48:e-abstract 4273
   Google Scholar
• Proksch JW, Granvil CP, Siou-mermet R, et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther 2009;25:335-44
   PubMed Web of Science ®Google Scholar
• Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 2004;24:150-60
   PubMed Web of Science ®Google Scholar
• Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004;24:161-7
   PubMed Web of Science ®Google Scholar
• Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83
   PubMed Web of Science ®Google Scholar
• Proksch JW, Chappa AK, Haas W, Morris TW. Besifloxacin, moxifloxacin, and gatifloxacin ocular tissue AUC/MIC ratios for fluoroquinolone-resistant organisms. Invest Ophthalmol Vis Sci 2009;50:e-abstract 2673
   Google Scholar
• Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009;25:1159-69
   PubMed Web of Science ®Google Scholar
• Karpecki P, DePaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009;31:514-26
   PubMed Web of Science ®Google Scholar
• McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009. [Epub 2009 July 28]
   Google Scholar
• Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991;112(Suppl 4):29-33S
   PubMedGoogle Scholar
• Morris TW, Hass W, Brunner LS, et al. Clinical efficacy of besifloxacin ophthalmic suspension; integrated microbiological analysis of 3 trials for topical treatment of bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:e-abstract 5945
   Google Scholar
• McDonald MB, Blondeau JM, DeCory HH, et al. Multidrug-resistant strains in clinical trials of besifloxacin in the treatment of bacterial conjunctivitis. Poster presented at the Annual Meeting of the American Academy of Ophthalmology, 8 – 11 November 2008 Atlanta, GA, USA
   Google Scholar
• Paterno MR, Comstock TL, Lynch JA, Usner DW. Besifloxacin ophthalmic suspension 0.6% is safe and well tolerated in the treatment of bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:e-abstract 2674
   Google Scholar
• US Food and Drug Administration. Division of Anti-Infective and Ophthalmologic Products Advisory Committee Meeting: Briefing package for besifloxacin hydrochloride ophthalmic suspension for the treatment of bacterial conjunctivitis. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-01-FDA.pdf [Last accessed 12 February 2009]
   Google Scholar
• Besivance [package insert]. Rochester, NY: Bausch & Lomb, Inc.
   Google Scholar